ALK and lung adenocarcinoma: A high prevalence of EGFR and ALK mutations was found in the lung adenocarcinoma of non-smokers with better survivals, which may benefit from the invention of suitable target therapies, and suggested different oncogenic mechanisms of the cancer itself that call for further investigations (40).